Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from AstraZeneca

AstraZeneca sees stock market value slump by more than £20bn after drug setback

The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.

Evening Standard · Jul 9

Global Market: European shares rebound as tech stocks recover; investors assess Middle East developments

European stock markets traded higher on Thursday, recovering from previous losses. Technology shares led the gains, driven by renewed interest in artificial intelligence demand. Oil prices eased despite ongoing geopolitical uncertainty in the Middle East region. Spanish equities outperformed regional peers after trade-related tensions eased. AstraZeneca shares tumbled significantly after…

The Economic Times · Jul 9

AstraZeneca shares slide after Ionis-partnered drug fails late-stage heart disease trial

AstraZeneca shares fell after Wainua failed a key trial. The drug did not reduce cardiovascular deaths or heart problems. Wainua showed no effect in patients already on stabilizer therapy. A subgroup taking the drug without stabilizers showed a nominal benefit. This setback impacts a projected two billion dollar sales opportunity.

The Economic Times · Jul 9

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks mixed as weak miners weigh in muted trade

Data showed the UK construction sector remained deep in contraction during June, although the pace of decline eased slightly from May’s six-year low.

Evening Standard · Jul 6

FTSE 100 rises as US jobs data eases Fed rate hike fears

The FTSE 100 closed up 174.53 points, 1.7%, at 10,652.87.

Evening Standard · Jul 2

Global drugmakers rush to boost US presence as tariff threat looms

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Companies are investing billions in new plants and expanding existing facilities across America. These moves aim to avoid penalties and ensure supply chains remain robust. Several major pharmaceutical firms have…

The Economic Times · Jun 15

First-in-Class Drug Targeting Treatment-Resistant High Blood Pressure Wins FDA Approval — and Works Like No Existing Drug

FDA approved baxdrostat (Baxfendy) on May 18, 2026 as the first-ever oral aldosterone synthase inhibitor for uncontrolled and resistant hypertension. BaxHTN Phase 3 (NEJM 2025): 8.7–9.8 mmHg additional systolic blood pressure reduction added to background therapy. Here is the full story.

Medical Daily · Jun 13

Read news from The Economist, FT, and more,
with one subscription

Breast cancer and endometriosis drug Zoladex is being pulled from Australia. How will women be affected?

The vital medicine, made by AstraZeneca, will not be available from November, possibly leaving thousands of women without treatment

The Guardian - AU · Jun 10

AstraZeneca daily pill shows promising weight loss results in trial

IN FULL

The Independent UK · Jun 10

New daily weight loss pill helps people shed 10 per cent of body weight

The pill doesn’t have the fasting requirements of many other weight loss drugs

The Independent UK · Jun 10

India a major growth market for Celonis, says senior exec

The Germany-based company said it already serves 260 global capability centres (GCCs) in India, counting companies such as Mercedes-Benz, Hitachi Energy and AstraZeneca as its clients, and sees a larger opportunity ahead as enterprises try to connect AI systems with operational data spread across departments and software systems.

The Economic Times · Jun 9

NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History

NEW YORK, June 5, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Ashley Mastronardi delivers the pre-market update on June 5thInvestors are reacting to the May jobs…

AAP · Jun 5

Low-dose Zoladex won’t be available in Australia from November. What might that mean for you?

The drug goserelin – commonly known as Zoladex – has been a quietly crucial medicine in Australia for decades.

The Conversation · Jun 4

A Key Endometriosis & Breast Cancer Drug Is Being Pulled From Australia: ‘Deeply Concerned’

AstraZeneca will discontinue the Zoladex 3.6mg implant in Australia from November 2026, affecting people with breast cancer and endometriosis.

Pedestrian.tv · Jun 4

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard · May 20

Women dying of breast cancer as life-extending drug remains blocked in England

A campaign is calling for Enhertu to be made available on the NHS.

MarketBeat · May 18

Compugen Q1 Earnings Call Highlights

Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company outlined first-quarter 2026 results and updates across its internal and partnered programs. On the

MarketBeat · May 18

As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade

With U.S. federal debt exceeding 100% of GDP, VXUS and IXUS offer investors international equity exposure as a hedge against rising sovereign risk.

MarketBeat · May 13

Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build

Alnylam Pharmaceuticals (NASDAQ:ALNY) Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance despite a slower first-quarter sequential growth rate, pointing to access, international launches and prescriber expansion as key drivers for the rest of the year

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat · May 13

Innate Pharma Q1 Earnings Call Highlights

Innate Pharma (NASDAQ:IPHA) said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502 in advanced solid tumors, and the AstraZeneca-partnered monalizumab program in non-small cell lung

International Business Times · May 5

White House Says Trump's Drugmaker Deals Could Save U.S. Economy $529 Billion Over 10 Years

The White House said on Tuesday that agreements with major drugmakers could save the U.S. economy $529 billion over the next decade.

MarketBeat · May 2

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Big Pharma stalwarts AbbVie, AstraZeneca, and GSK beat Q1 revenue expectations, raising guidance and offering a potential tailwind for the flailing medical sector.

Fortune · Apr 30

How AstraZeneca's 17,000 AI-certified employees are helping it reach a 'stretch goal' of $80 billion in revenue

CFO Aradhana Sarin breaks down the building blocks behind the revenue target and reflects on a strong Q1.

Evening Standard · Apr 29

FTSE 100 closes lower as drugs firms GSK and AstraZeneca struggle

The Independent UK · Apr 29

Pharmaceutical giant to invest £300m in Britain after UK-US deal

IN FULL

The Independent UK · Apr 29

AstraZeneca to inject £300 million into UK in surprise U-turn

AstraZeneca chief executive Pascal Soriot has thanked the Government ‘for their efforts to improve access for patients’

1 2 3 4 5

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.